Using routine programmatic data to measure HIV incidence among pregnant women in Botswana

Abstract

Introduction Pregnant women in sub-Saharan Africa have high risk of HIV acquisition, yet approaches for measuring maternal HIV incidence using routine surveillance systems are undefined. We used programmatic data from routine antenatal care (ANC) HIV testing in Botswana to measure real-world HIV incidence during pregnancy. Methods From January 2018 to September 2019, the Botswana Ministry of Health and Wellness implemented an HIV testing program at 139 ANC clinics. The program captured information on testers’ age, testing date and result, and antiretroviral treatment (ART) initiation. In our analysis, we excluded individuals who previously tested HIV-positive prior to their first ANC visit. We defined incident HIV infection as testing HIV-positive at an ANC visit after a prior HIV-negative result within ANC. Results Overall, 29,570 pregnant women (median age 26 years, IQR 22–31) tested for HIV at ANC clinics: 3% (836) tested HIV-positive at their first recorded ANC visit and 97% tested HIV-negative (28,734). Of those who tested HIV-negative, 28% (7940/28,734) had a repeat HIV test recorded at ANC. The median time to HIV re-testing was 92 days (IQR 70–112). In total, 17 previously undiagnosed HIV infections were detected (HIV incidence 8 per 1000 person-years, 95% CI 0.5–1.3). ART initiation among women newly diagnosed with HIV at ANC (853) was 88% (671/762). Conclusions In Botswana, real-world HIV incidence among pregnant women at ANC remains above levels of HIV epidemic control (≤ 1 per 1000 person-years). This study shows how HIV programmatic data can answer timely population-level epidemiological questions and inform ongoing implementation of HIV prevention and treatment programs.

Transactional sex and age-disparate sexual partnerships among adolescent girls and young women in Tanzania

“…Wellcontrolled research studies may also exclude adolescents who are most at risk for poor sexual and reproductive health outcomes such as those who live and work on the street, potentially limiting generalizability of findings (66,67). Yet programmatic data remain a relatively under-utilized resource to examine the effectiveness of HIV-related interventions and implementation strategies for key populations (68)(69)(70)(71). As programs continue to roll out biomedical prevention interventions for AGYW such as longacting PrEP, program data offer an opportunity to keep pace and quickly tailor and adapt implementation strategies, thus providing for a more nuanced and more efficient HIV response.…”

Barriers to and strategies for early implementation of pharmacy-delivered HIV PrEP services in Kenya: An analysis of routine data

“…For example, documenting implementation activities provides information for implementers, key evaluation stakeholders, and individuals who wish to implement similar interventions and can help inform how they might adapt or modify support activities to enhance implementation ( 11 ). Routinely collected programmatic data is increasingly being recognized as an important data source in implementation science that can capture the implementation process and help identify early implementation barriers and actions taken to address these ( 12 , 13 ). Compared to participant-level research data, it is often collected more frequently throughout implementation, is less expensive to collect, and can capture more system-level implementation barriers and strategies.…”

Determinants of Community HIV Index Testing among HIV Index Clients in Yirol West County, South Sudan

“…Worldwide 39 million individuals remained living with HIV/AIDS in 2022 and 2.58 million individuals became recently infected with HIV/AIDS in 2022 and roughly 624,000 individuals deceased from AIDS-associated sicknesses. In 2022 alone, it's estimated that 28.7 million persons remained receiving ARVs therapy in 2022 and 79.3 million individuals have developed diseased with HIV from the time when the start of the HIV widespread [1]. Since then, it is estimated that around 36.3 million individuals have deceased from HIV/AIDS-associated infections from the time when the start of widespread [1].…”

“…In 2022 alone, it's estimated that 28.7 million persons remained receiving ARVs therapy in 2022 and 79.3 million individuals have developed diseased with HIV from the time when the start of the HIV widespread [1]. Since then, it is estimated that around 36.3 million individuals have deceased from HIV/AIDS-associated infections from the time when the start of widespread [1]. Of the 37.9 million persons alive with HIV/AIDS worldwide, comprising 25.6 million live in Sub-Saharan Africa.…”

“…Of the 37.9 million persons alive with HIV/AIDS worldwide, comprising 25.6 million live in Sub-Saharan Africa. 21% continue ignorant of their HIV/AIDS conditions [1].…”